Additional file 3: of Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity
- Martina Ott (126789)
- Erika Avendaño-Guzmán (6404882)
- Evelyn Ullrich (5280524)
- Carolin Dreyer (6404885)
- Judith Strauss (6404888)
- Markus Harden (3949568)
- Margarete Schön (3111897)
- Michael Schön (6404891)
- Günter Bernhardt (657251)
- Christine Stadelmann (137943)
- Christiane Wegner (6404894)
- Wolfgang Brück (251206)
- Stefan Nessler (6404897)
Publication date
February 2019
DOIAbstract
Figure S3. (A) Representative flow cytometry of splenic NK1.1/AhR expression in MOG35–55 immunized mice. (B) Representative flow cytometry analysis of NK1.1/ CD69 expression in naïve C57BL/6 or AhR−/− mice treated for 11 days with 25 mg/kg laquinimod or vehicle. (C) Representative flow cytometry analysis of DCs in the spleens of C57BL/6 and AhR-deficient mice treated with 25 mg/kg laquinimod or vehicle for 11 days. ***P < 0.001, two-way ANOVA. (TIF 1044 kb
Add to ORKG